NEW YORK, Oct. 29, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company") (Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
Click here to learn about the case: http://docs.wongesq.com/ENZY-Info-Request-Form-450. There is no cost or obligation to you.
The complaint alleges that Enzymotec's Registration Statement and Prospectus contained materially false and misleading statements and omitted material information, and that throughout the Class Period the Company misrepresented and/or failed to disclose material information.
If you suffered a loss in Enzymotec you have until November 4, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ENZY-Info-Request-Form-450.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: firstname.lastname@example.orgSource:The Law Offices of Vincent Wong